Short-term Effects of Inhaled β-Adrenergic Agonist on Breathlessness and Central Inspiratory Drive in Patients With Nonreversible COPD

Pino-García, José M.; García‐Río, Francisco; Gómez, Luis; Racionero, Miguel A.; Diaz-Lobato, Salvador; Villamor, J.

doi:10.1378/chest.110.3.637

Cited by 11 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since NRD is closely associated with disease severity and changes in the perception of dyspnea, it has served as a physiological biomarker for monitoring the changes during acute exacerbations of COPD (18). Previous studies have shown that inhaled bronchodilators can decrease central inspiratory drive and improve dyspnoea in COPD patients (19,20). As expected, the NRD of all patients in the present study decreased significantly after inhaled bronchodilators.…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Efficiency of neural respiratory drive for the assessment of bronchodilator responsiveness in patients with chronic obstructive pulmonary disease: an exploratory study

Li³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Conventional lung function parameters, such as forced vital capacity (FVC), forced expiratory volume in 1 second (FEV 1 ) and inspiratory capacity (IC) are often used to assess the therapeutic outcomes of bronchodilators, but they lack sensitivity. A novel indicator, namely efficiency of neural respiratory drive (NRD), may objectively evaluate the physiological changes in patients with chronic obstructive pulmonary disease (COPD). We investigated whether this indicator could be used to more accurately assess the responsiveness to inhaled bronchodilators. Methods: Thirty-six subjects with moderate-to-severe COPD were randomized into group A (n=18) and group B (n=18). Participants in group A inhaled 400 μg placebo, 400 μg salbutamol and 80 μg ipratropium in sequence whereas those in group B had the salbutamol and ipratropium reversed.

show abstract

Section: Discussionsupporting

confidence: 81%

“…Then an average variability of each index at four time points was calculated as follows: the average aberration rate (%) were 7.41±5. 19 …”

Section: Resultsmentioning

confidence: 99%

Efficiency of neural respiratory drive for the assessment of bronchodilator responsiveness in patients with chronic obstructive pulmonary disease: an exploratory study

Li³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…Short‐acting β 2 ‐adrenergic receptor agonists (SABAs), such as terbutaline and albuterol are often used on an as‐needed basis to relieve symptoms because they elicit a rapid onset of action (1), achieve maximum bronchodilatory effects shortly after administration (39), and provide effective bronchodilation for approximately 4–6 h (39). Terbutaline at high doses has also been shown to improve bronchodilation in patients with severe COPD (45) and to improve dyspnoea in patients with irreversible COPD (46).…”

Section: Pharmacologic Treatment In the Management Of Copdmentioning

confidence: 99%

A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD

Fromer

Cooper

2008

International Journal of Clinical Practice

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the USA, and represents a major health, social and economic burden. COPD is underdiagnosed and often misdiagnosed, which likely contributes to the continuing increases in the prevalence, morbidity and mortality associated with this disease. This is unfortunate because whereas COPD cannot be cured, it can be treated effectively, particularly during the earlier stages of the disease. Evidence-based guidelines, developed to assist in the prevention, diagnosis and management of COPD, are available to healthcare professionals interested in learning more about COPD. These guidelines are updated and revised on a regular basis to reflect recent advances in our understanding of the pathophysiology of and treatments available for COPD. Nevertheless, primary-care physicians have reported a lack of awareness of the fundamental concepts underpinning the optimal treatment and management of COPD presented in the guidelines. Thus, the objective of this article is to summarise key physiologic, diagnostic and management concepts provided in the most recent update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, which were published in November 2006.

show abstract

“…1,4 Randomized clinical trials have demonstrated that these medications can improve lung function and reduce the severity of breathlessness in such patients. [5][6][7] Most clinical experience with inhaled ␤ 2 -agonists has been with short-acting agents whose actions last 4 to 6 h. Salmeterol xinafoate is a long-acting preparation with a 12-h duration of action that has been used effectively in the treatment of asthma. Twice daily administration of salmeterol (42 g) is the optimum dosing regimen for patients with mild-to-moderate reversible airways obstruction.…”

mentioning

confidence: 99%

Efficacy of Salmeterol Xinafoate in the Treatment of COPD

Mahler¹,

Donohue

Barbee

et al. 1999

Chest

466

300

View full text Add to dashboard Cite

Short-term Effects of Inhaled β-Adrenergic Agonist on Breathlessness and Central Inspiratory Drive in Patients With Nonreversible COPD

Cited by 11 publications

References 25 publications

Efficiency of neural respiratory drive for the assessment of bronchodilator responsiveness in patients with chronic obstructive pulmonary disease: an exploratory study

Efficiency of neural respiratory drive for the assessment of bronchodilator responsiveness in patients with chronic obstructive pulmonary disease: an exploratory study

A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD

Efficacy of Salmeterol Xinafoate in the Treatment of COPD

Contact Info

Product

Resources

About